Attached files

file filename
EX-32.2 - EX-32.2 - Allovir, Inc.alvr-ex322_6.htm
EX-31.2 - EX-31.2 - Allovir, Inc.alvr-ex312_8.htm
EX-31.1 - EX-31.1 - Allovir, Inc.alvr-ex311_9.htm
EX-23.1 - EX-23.1 - Allovir, Inc.alvr-ex231_952.htm
EX-10.20 - EX-10.20 - Allovir, Inc.alvr-ex1020_1061.htm
EX-10.19 - EX-10.19 - Allovir, Inc.alvr-ex1019_1062.htm
EX-10.18 - EX-10.18 - Allovir, Inc.alvr-ex1018_1063.htm
EX-10.17 - EX-10.17 - Allovir, Inc.alvr-ex1017_627.htm
EX-4.2 - EX-4.2 - Allovir, Inc.alvr-ex42_626.htm
10-K - 10-K - Allovir, Inc.alvr-10k_20201231.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of AlloVir, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: February 12, 2021

 

By:

 

/s/ David Hallal

 

 

 

 

David Hallal

 

 

 

 

Chief Executive Officer and Director

(Principal Executive Officer)